- Home
- PRGO vs APLS Comparison
PRGO vs APLS Comparison
Compare PRGO & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGO
- APLS
- Stock Information
- Founded
- PRGO 1887
- APLS 2009
- Country
- PRGO Ireland
- APLS United States
- Employees
- PRGO N/A
- APLS N/A
- Industry
- PRGO Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- PRGO Health Care
- APLS Health Care
- Exchange
- PRGO Nasdaq
- APLS Nasdaq
- Market Cap
- PRGO 3.9B
- APLS 4.4B
- IPO Year
- PRGO 1991
- APLS 2017
- Fundamental
- Price
- PRGO $26.61
- APLS $34.63
- Analyst Decision
- PRGO Buy
- APLS Buy
- Analyst Count
- PRGO 4
- APLS 19
- Target Price
- PRGO $37.00
- APLS $49.89
- AVG Volume (30 Days)
- PRGO 1.2M
- APLS 3.6M
- Earning Date
- PRGO 11-06-2024
- APLS 11-05-2024
- Dividend Yield
- PRGO 4.16%
- APLS N/A
- EPS Growth
- PRGO N/A
- APLS N/A
- EPS
- PRGO N/A
- APLS N/A
- Revenue
- PRGO $4,392,000,000.00
- APLS $715,216,000.00
- Revenue This Year
- PRGO N/A
- APLS $95.53
- Revenue Next Year
- PRGO $4.51
- APLS $12.94
- P/E Ratio
- PRGO N/A
- APLS N/A
- Revenue Growth
- PRGO N/A
- APLS 162.10
- 52 Week Low
- PRGO $23.89
- APLS $24.34
- 52 Week High
- PRGO $34.60
- APLS $73.80
- Technical
- Relative Strength Index (RSI)
- PRGO 39.43
- APLS 60.79
- Support Level
- PRGO $27.79
- APLS $31.76
- Resistance Level
- PRGO $28.62
- APLS $34.98
- Average True Range (ATR)
- PRGO 0.58
- APLS 1.59
- MACD
- PRGO -0.27
- APLS -0.07
- Stochastic Oscillator
- PRGO 2.12
- APLS 69.95
About PRGO Perrigo Company plc
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.